The role of radionuclide therapy in medullary thyroid cancer

Tumori

Volumn 89, Issue 5, 2003, Pages 560-562

  Castellani, Maria Rita ^a   Alessi, Alessandra ^a   Savelli, Giordano ^a   Bombardieri, Emilio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Medullary thyroid cancer; Metaiodobenzylguanidine therapy; Nuclear medicine therapy; Radionuclide therapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; RADIOISOTOPE;

ARTICLE; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; DRUG TUMOR LEVEL; HUMAN; PROGNOSIS; RADIATION DOSE DISTRIBUTION; SENSITIVITY AND SPECIFICITY; TARGET ORGAN; THYROID MEDULLARY CARCINOMA; THYROID SCINTISCANNING; TREATMENT INDICATION;

EID: 0346366717     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160308900523     Document Type: Article

References (21)

1. Orlandi F, Caraci P, Mussa A, Saggiorato E, Pancani G, Angeli AL: Treatment of medullary thyroid carcinoma: an update. Endocr Relat Cancer, 8: 135-147, 2001.
2. Hyer SL, Vini L, Hern RA, Harmer C: Medullary thyroid cancer: multivariate analysis of prognostic factors influencing survival. Eur J Surg Oncol, 26: 686-690, 2002.
3. Vitale G, Caraglia M, Ciccarelli A, Luppoli G, Abruzzese A, Tagliaferro P: Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer, 91: 1797-1808, 2001.
4. Schlumberger M, Pacini F: Medullary thyroid carcinoma. In: Thyroid tumors, Schlumberger M, Pacini F (Eds), pp 267-299, Nucleon, Paris, 1999.
5. Hoefnagel CA, Delprat CC, Valdès Olmos RA: Role of 131I-metaiodobenzylguanidine therapy in medullary thyroid carcinoma. J Nucl Biol Med, 35: 334-336, 1991.
6. Rufini V, Salvatori M, Garganese MC, Di Giuda D, Lodovica Maussier M, Troncone L: Role of nuclear medicine in the diagnosis and therapy of medullary thyroid carcinoma. Rays, 25: 273-282, 2000.
7. Bombardieri E, Maccauro M, Castellani MR, Chiti A, Procopio G, Bajetta E, Seregni E: Radioisotopic imaging of neuroendocrine tumors. Which radiopharmaceutical and which diagnostic procedure? Minerva Endocrinol, 26: 197-213, 2001.
8. Brandt-Mainz K, Muller SP, Gorges R, Saller B, Bockisch A: The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med, 27: 490-496, 2000.
9. Hoefnagel CA: MIBG and radiolabelled octreotide in neuroendocrine tumors. Q J Nucl Med, 39: 137-139, 1995.
10. Chatal J-F, Hoefnagel CA: Radionuclide therapy. Lancet, 354: 931-935, 1999.
11. Saad MF, Guido JJ, Samaan NA: Radioactive iodine in the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab, 57: 124-128, 1983.
12. Troncone L, Galli G: Proceedings of the International Workshop on the role of 131I-metaiodobenzylguanidine in the treatment of neural crest tumors. J Nucl Biol Med, 35: 177-362, 1991.
13. Shapiro B, Sisson JC, Shulkin BL, Gross MD, Zempel S: The current status of radioiodinate metaiodobenzylguanidine therapy of neuro-endocrine tumors. Q J Nucl Med, 39 (Suppl 1): 55-57, 1995.
14. Troncone L, Rufini V: 131I-MIBG therapy of neural crest tumours (review). Anticancer Res, 17: 1823-1832, 1997.
15. Castellani MR, Chiti A, Seregni E, Bombardieri E: Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumors. Q J Nucl Med, 44: 77-87, 2000.
16. Mukherjee JJ, Kaltsas GA, Islam N: Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with 131I-metaiodobenzylguanidine (131I-MIBG). Clin Endocrinol, 55: 47-60, 2001.
17. Stein R, Chen S, Reed L, Richel H, Goldenberg DM: Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma. Cancer, 94: 51-61, 2002.
18. Juweid M, Haijar G, Swayne LC, Sharkey RM, Suleiman S, Herskovic T, Pereira M, Rubin AD, Goldemberg DM: Phase I/II trial of 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer, 85: 1828-1842, 1999.
19. Kraeber-Bodèrè F, Bardet S, Hoefnagel CA, Vieira MR, Vuillez J-P, Murat A, Ferreira TC, Bardiès M, Ferrer L, Resche I, Gautherot E, Rouvier E, Barbet J, Chatal JF: Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labelled bivalent hapten: preliminary results of a phase I/II clinical trial. Clin Cancer Res, 5 (Suppl): 3190S-3198S, 1999.
20. Kraeber-Bodèrè F, Sai-Maurel C, Campioi L, Faivre-Chauvet A, Miralliè E, Cheiel M, Supiot S, Barbet J, Chatal J-F, Thedrez P: Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. Mol Cancer Ther, 1: 267-274, 2002.
21. Waldherr C, Schumacher T, Pless M, Crazzolara A, Maecke HR, Nitzsche EU, Hadelmann A, Mueller-Brand J: Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using [90Y]-DOTA-D-Phel-Tyr3-octreotide: a pilot study. Nucl Med Comm, 22: 673-678, 2001.